General ENT News

ENT

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lynch E et al. - The authors discuss a compound currently in Phase II clinical testing for the prevention and treatment of noise-induced hearing loss. This article will review the historic background and pertinent preclinical and clinical data available for ebselen, a novel drug that mimics the activity of glutathione peroxidase, a catalytic antioxidant enzyme that is essential for the peripheral auditory system.

Related Articles

Additional heterozygous 2507A>C mutation of WFS1 in progressive hearing loss at lower frequencies
The Laryngoscope, 11/05/09    Relevance Score: 68%

High incidence of hearing loss in long-term survivors of multisystem langerhans cell histiocytosis
Pediatric Blood & Cancer, 10/22/09    Relevance Score: 68%

Acoustic analysis of voice in cochlear implant recipients with post-meningitic hearing loss
Cochlear Implants International, 10/07/09    Relevance Score: 68%

Acute-Onset Unilateral Psychogenic Hearing Loss in Adults: Report of Six Cases and Diagnostic Pitfalls
Journal for Oto-Rhino-Laryngology, 10/23/09    Relevance Score: 67%

Diagnosing hearing problems
Paediatrics and Child Health, 10/06/09    Relevance Score: 67%

Today in Otology/Neurotology...keeping you current

Comparison between topical honey and mafenide acetate in treatment of auricular burn
American Journal of Otolaryngology, 11/30/09

Cholesteatoma
ENT Journal, 11/30/09

New Patterns in the Otopathogens Causing Acute Otitis Media Six to Eight Years After Introduction of Pneumococcal Conjugate Vaccine
The Pediatric Infectious Disease Journal, 11/25/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address